DoD Prostate Cancer Research Program Funding Opportunities - July Deadlines

How to Apply: 

The FY22 Defense Appropriations Act is anticipated to provide funding for the PCRP to support innovative, high-impact prostate cancer research.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

 

The FY22 PCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

 

The mission of the FY22 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease.  Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY22 PCRP Overarching Challenges:

 

  • ·        Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  Studies should consider both short- and long-term quality of life outcomes.  Areas of particular interest include:

o   The mental and emotional health of patients and their families/caregivers

o   Impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   Identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   Translation of factors or interventions that improve quality of life outcomes and overall health and wellness

  • ·        Develop treatments that improve outcomes for men with lethal prostate cancer

Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

  • ·        Advance health equity and reduce disparities in prostate cancer

Applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans.

Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

  • ·        Define the biology of prostate cancer progression to lethal prostate cancer to reduce death

Applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

Early Investigator Research Award – Letter of Intent Due by July 7, 2022

By March 31, 2023, Postdoctoral Principal Investigators (PIs):

  • ·      Must possess a doctoral degree (or equivalent)
  • ·      Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)
  • ·      Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
  • ·      PIs must have a designated mentor who is an experienced prostate cancer researcher.
  • ·      Must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development.
  • ·      Must address at least one of the FY22 PCRP Overarching Challenges.
    • ·     The maximum allowable funding for the entire period of performance is $300,000 for direct costs.
    • ·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
    • ·     The maximum period of performance is years.

 

Physician Research Award – Letter of Intent Due by July 7, 2022

At the time of application submission, the PI must be either:

  • ·    In the last year of an accredited medical residency or medical fellowship program

or

Within 5 years of having initiated a faculty appointment (including Instructor positions)

  • ·     Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
  • ·     PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
  • ·     PIs must have a designated mentor with an established research program in prostate cancer.
  • ·     Applications are strongly encouraged to demonstrate protection of at least 40% of the PI’s time for prostate cancer research (not required to be exclusive to this award). 
  • ·     Must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development.
  • ·     Must address at least one of the FY22 PCRP Overarching Challenges.
  • ·     The maximum allowable funding for the entire period of performance is $750,000 for direct costs.
  • ·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • ·     The maximum period of performance is 4 years.

Idea Development Award – Letter of Intent Due by July 7, 2022

Established Investigators:  Independent investigators at all levels

New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

  • ·      Have the freedom to pursue individual aims without formal mentorship
  • ·      Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award
  • ·      Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave)
    • ·      Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY22 PCRP Overarching Challenges.
    • ·      Emphasis is equally placed on Innovation and Impact.
    • ·      Preliminary data are encouraged, but not required.
    • ·      Clinical trials are not allowed.
    • ·      Multidisciplinary projects are encouraged, and multi-institutional projects are allowed.
    • ·      Must address at least one of the FY22 PCRP Overarching Challenges.
    • ·     The maximum allowable funding for the entire period of performance is $900,000 for direct costs.
    • ·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
    • ·     The maximum period of performance is years.
       
       
      For more information, please contact Jill Sherman, International Research Facilitator at  intl.research@lakeheadu.ca.
External Deadline: 
Thursday, July 7, 2022
Funding Source: 
External
Funding Level: 
Research